timothy sykes logo

Stock News

Altimmune Stock Plummets After Disappointing Trial Results

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 12/21/2025, 8:13 am ET 12/21/2025, 8:13 am ET | 6 min 6 min read
Altimmune Stock Plummets After Disappointing Trial Results Thumbnail

Altimmune Inc.’s stocks have been trading down by -21.39 percent amid concerns over delays in clinical trials impacting investor sentiment.

Healthcare industry expert:

Analyst sentiment – negative

Altimmune (ALT) is currently in a challenging market position, evidenced by critical financial metrics. The company reported a pretax profit margin of -6149.7, indicating substantial pre-tax losses relative to revenue. With total revenue of only $20,000 and a drastic decline in revenue over the last three to five years, the financial health is questionable. Their enterprise value of $364.47 million seems optimistic against the scale of net income losses reported at -$19,014,000, compounded by negative free cash flow of -$11,897,000. With a current ratio of 17.2, the company maintains liquidity but fails to translate this into effective profitability due to a negative return on assets of -43.88. These figures clearly point to a precarious position requiring strategic overhaul to halt diminishing returns.

The recent weekly price pattern analysis for ALT shows a significant drop from $5.13 to $3.97, with a sharp decline observed on 12/19 following poor trial results. A downtrend characterizes the current momentum, confirmed by a dominant bearish candle. The price action from 12/19 indicates high volatility, underscoring a probable continuation of the bearish trend. A prudent strategy would involve short positions at resistant levels near $4.05, with stop-loss orders slightly above $4.10 and profit-taking near recent support levels around $3.88. The volume spike accompanying this price drop suggests market sentiment turned decisively negative, providing a strong signal for cautious trading.

The recent catalyst, a 21% decline in stock price due to underwhelming Phase 2b MASH trial outcomes, has contributed to a negative sentiment. This performance is significantly below Healthcare and Biotechnology benchmarks, where peers are in better standing. Current resistance appears to be at $4.05, with support likely at $3.88. The failure to meet clinical endpoints diminishes near-term opportunities for valuation recovery, leading me to assign a negative outlook. In the absence of new positive data or strategic pivots, sustaining levels above $4 seems improbable.

Candlestick Chart

Weekly Update Dec 15 – Dec 19, 2025: On Sunday, December 21, 2025 Altimmune Inc. stock [NASDAQ: ALT] is trending down by -21.39%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Altimmune’s recent financial performance has been under scrutiny amid the fallout from its trial results. The company’s revenues have seen a dramatic decline over the past years, impacting its overall valuation. Recent earnings reports indicate a company in financial turbulence, with the net income from continuing operations reaching a negative $19.01M by the end of Q3 2025. The outstanding basic earnings per share is a troubling -$0.21, reflective of continuous financial strain.

The gross margin remains high at 100%, hinting at optimization in cost structures despite revenue woes. However, key profitability ratios like the pre-tax profit margin, an alarming -6149.7, underscore severe limits in converting revenue into actual profit. The asset turnover is stagnant, as seen with a zero receivables turnover, raising concerns about operational efficiencies and capital utilization. Financial health indicators like the current ratio have held steady at 17.2, but the ability to leverage capital effectively remains questionable with long-term debt over equity ratios at 0.07. This presents a cautious outlook for short-term debt obligations, suggesting some resilience but limited growth avenues without strategic inflexions.

The recent news has exacerbated market perceptions of risk in holding ALT stock. Investment cash flows are notably negative at $149.32M, affecting their cash reserves, which dwindled to $24.31M by September 30, 2025. Cash from financing activities, however, shows positive movements as capital stocks were issued, accumulating $39.64M, demonstrating some capacity for raising funds despite underlying losses. Moving forward, the trials’ failure adds pressure on the management to reassess strategic planning with more precision to stabilize investor trust and drive stock performance upward again.

More Breaking News

Conclusion

In conclusion, Altimmune’s stock faces a challenging landscape after its Phase 2b MASH trial did not meet the desired success metrics, triggering a 21% stock drop. Financial indicators offer a mixed view, with strong margins but weak profitability and inefficient asset use highlighting ongoing challenges. The immediate market reaction reflects skepticism about the firm’s ability to pivot strategically and derive value from upcoming initiatives. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” Traders are now searching for reassuring signs of recovery and revaluation strategies that could revitalize ALT’s market presence and stock stability. The imperative for Altimmune is to translate scientific research into financially secure ventures effectively, a task underscored by the current trader climate demanding actionable results.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”